CrossMark

# Transcriptional profiling of chronic clinical hepatic *schistosomiasis japonica* indicates reduced metabolism and immune responses

# GEOFFREY N. GOBERT<sup>1</sup>\*<sup>†</sup>, MELISSA L. BURKE<sup>1</sup><sup>†</sup><sup>‡</sup>, DONALD P. MCMANUS<sup>1</sup>\*<sup>†</sup>, MAGDA K. ELLIS<sup>1</sup><sup>§</sup>, CANDY CHUAH<sup>1,2,3</sup>, GRANT A. RAMM<sup>1</sup>, YUANYUAN WANG<sup>4</sup> and YUESHENG LI<sup>1,4</sup>

<sup>1</sup> QIMR Berghofer Medical Research Institute, Brisbane, Qld 4006, Australia

<sup>2</sup> School of Veterinary Sciences, The University of Queensland, Gatton, Qld 4343, Australia

<sup>3</sup> School of Medical Sciences, Universiti Sains Malaysia, 16150, Kelantan, Malaysia

<sup>4</sup> Hunan Institute of Parasitic Diseases, WHO Collaborating Centre for Research and Control of Schistosomiasis in the Lake Region, China

(Received 19 February 2015; revised 19 April 2015; accepted 3 May 2015; first published online 28 July 2015)

#### SUMMARY

Schistosomiasis is a significant cause of human morbidity and mortality. We performed a genome-wide transcriptional survey of liver biopsies obtained from Chinese patients with chronic schistosomiasis only, or chronic schistosomiasis with a current or past history of viral hepatitis B. Both disease groups were compared with patients with no prior history or indicators of any liver disease. Analysis showed in the main, downregulation in gene expression, particularly those involved in signal transduction via *EIF2 signalling* and *mTOR signalling*, as were genes associated with cellular remodelling. Focusing on immune associated pathways, genes were generally downregulated. However, a set of three genes associated with granulocytes, MMP7, CLDN7, CXCL6 were upregulated. Differential gene profiles unique to schistosomiasis included the gene Granulin which was decreased despite being generally considered a marker for liver disease, and IGBP2 which is associated with increased liver size, and was the most upregulated gene in schistosomiasis only patients, all of which presented with hepatomegaly. The unique features of gene expression, in conjunction with previous reports in the murine model of the cellular composition of granulomas, granuloma formation and recovery, provide an increased understanding of the molecular immunopathology and general physiological processes underlying hepatic schistosomiasis.

Key words: Schistosomiasis, Schistosoma, hepatic fibrosis, transcriptomics, clinical, liver.

#### INTRODUCTION

Schistosomiasis is an endemic tropical disease in many parts of the world, with 600 million people at risk due to inadequate hygiene, treatment and control programs. The pathology associated with hepatic schistosomiasis ranges from headache, lethargy and fever, to hepatic fibrotic obstruction, with the latter leading to complications such as portal hypertension, ascites and hepato-splenomegaly and, in extreme cases, death (Ross *et al.* 2002). Recent meta-analysis of the disease indicates that, in terms of morbidity and mortality, the burden on individuals and communities due to schistosomiasis has increased worldwide with disability-adjusted life years (DALY)

<sup>‡</sup> Present address: Division of Mycobacterial Research, National Institute for Medical Research, London NW7 1AA, UK.

*Parasitology* (2015), **142**, 1453–1468. © Cambridge University Press 2015 doi:10.1017/S0031182015000682

estimates rising approximately 20% from 40 to 48 per 100 000 in the past 20 years (Murray *et al.* 2013).

The basis of the pathology arising from a schistosome infection is the host's immune response against parasite eggs trapped within tissues, leading to the formation of granulomas (Gryseels et al. 2006). The majority of disease pathology forms at the sites of egg deposition, which is mainly the liver in the case of Schistosoma mansoni and Schistosoma japonicum or the genitourinary tract in Schistosoma haematobium infections (Gryseels et al. 2006). Granuloma formation limits the damage caused by hepatotoxic compounds released by parasite eggs, by partitioning and/or elimination, but this process may also lead to extensive fibrogenesis within host tissues (Wilson et al. 2007). Many of the general features of granuloma formation within the liver have been investigated, particularly with reference to the S. mansoni murine model (Burke et al. 2009). A CD4 + Th2 response drives the formation of hepatic granulomas leading to host pathology (Chuah et al. 2014a). Th2 cytokines, predominantly IL-4 and IL-13, promote this response, while IL-10, IFN- $\gamma$ , IL13R $\alpha$ 2 and a subset of regulatory T-cells (T-Regs) and alternatively activated

<sup>\*</sup> Corresponding authors. QIMR Berghofer Medical Research Institute, Brisbane, Qld 4006, Australia. Email: Don.McManus@qimrberghofer.edu.au; Geoffrey. Gobert@qimrberghofer.edu.au

<sup>&</sup>lt;sup>†</sup> These authors contributed equally.

<sup>§</sup> Present address: Tuberculosis Research Group, Centenary Institute, Sydney, NSW 2042, Australia.

macrophages (AAM) $\varphi$ , act to restrict the immune response and the pathology associated with schistosomiasis (Chuah *et al.* 2014*a*).

We have previously published studies on the transcriptional events that coincide with hepatic pathology using the schistosomiasis japonica murine model (Burke et al. 2010a, b; Perry et al. 2011; Chuah et al. 2013). These studies present the analysis of egg-induced hepatic granuloma/fibrosis formation; with a focus on the chemokines and cytokines elevated during disease (Burke et al. 2010b) and the events required for cellular recruitment to the liver and site of disease pathology (Burke et al. 2010a). Following studies provided a transcriptional framework to explain contrasting hepatic pathology in two inbred mouse strains infected with S. japonicum and indicated the importance of neutrophils in restricting pathology (Perry et al. 2011). We then produced a gene atlas of the granuloma, increasing our resolution of the transcriptional responses associated with hepatic schistosomiasis (Chuah et al. 2013). This latter study reaffirmed the importance of neutrophils in hepatic granuloma formation, and suggested two distinct roles for neutrophils extracellular traps in recruiting other immunological cells and in controlling fibrosis (Chuah et al. 2014b). These roles for neutrophils appear to be unique to the disease caused by S. japonicum and not S. mansoni. While our findings, and those of others, have provided a good appreciation of the cellular and molecular events that occur during hepatic schistosomiasis, they have been restricted to animal models and insights from clinical sources have been much more limited.

We have previously reported the collection and histological characterization of a large biopsy study in Hunan Province, The People's Republic of China, where patients underwent splenectomy and liver biopsy for the treatment of advanced schistosomiasis japonica (Li et al. 2011). Various clinical parameters were recorded including liver function tests, serology for hepatitis B/C/D, ultrasound diagnostic grading, and histology of liver biopsies. These cases represented a unique cohort of patients with advanced schistosomiasis in which the presence of S. japonicum eggs caused inflammation and distinct hepatic periportal fibrosis, leading to portal hypertension, hepatosplenomegaly and ascites (Li et al. 2011). Most patients were also sero-positive for hepatitis B. The degree of fibrosis ranged from grade II-III as determined by ultrasound and grade III-IV by histology. This work provided unique clinical data for advanced clinical schistosomiasis, with useful histological assessments of fibrosis. In the present paper we report the results of comprehensive transcriptional profiling of a subset of this unique clinical tissue collection, with the aim of providing some novel molecular insights on the aetiology of this chronic disease.

#### MATERIALS AND METHODS

#### Ethics statement

All work was conducted with approval from the human ethics committees of Hunan Institute of Parasitic Disease, China, and QIMR Berghofer Medical Research Institute, Australia (P919). Written informed consent was obtained from all subjects.

#### Patients

A subset of 13 liver biopsies, from long-term residents of the schistosomiasis-endemic Dongting Lake area, Hunan Province, People's Republic of China, was selected based on a clinical diagnosis of advanced schistosomiasis. The methods used to assess the clinical, parasitological and serological status of these patients have been reported (Li et al. 2011). All schistosomiasis patients were symptomatic and had splenomegaly (Hackett criteria ≥II) according to published classification criteria. Patients were classified as either 'schistosomiasis only' ([S]) or 'schistosomiasis and hepatitis B' ([SH]) on the basis of fibrosis grading, schistosomiasis history indicated by questionnaire and serology results (Li et al. 2011). All patients were subsequently hospitalized and underwent surgery at Xiang-Yue Hospital, Yueyang, an affiliated hospital of Hunan Institute of Parasitic Diseases, in the Dongting Lake region. Surgical intervention included splenectomy, left gastric vein ligature and devascularization of the great curvature of the stomach for treatment of portal hypertension as described (Li et al. 2011). A further four liver biopsies were collected from control patients ([C]) who were from areas nonendemic for schistosomiasis. These samples were obtained from individuals undergoing abdominal surgery (for removal of gallstones) or emergency abdominal surgery following a traffic accident. A medical questionnaire was used to obtain details of medical history and demographics for the 17 patients, all of whom provided written informed consent allowing the collection and use of the biopsied material.

#### Microarray analysis

Total RNA was extracted from liver tissue biopsies using Trizol (Life Technologies, Carlsbad, USA) and an RNeasy Mini Kit (Qiagen, Valencia, USA). Total RNA quantity was measured using a Nanodrop-1000 (Nanodrop Technologies) and quality was assessed using an Agilent Bioanalyzer (Agilent Technologies, Foster City, USA). cRNA was synthesized using the Illumina Total Prep RNA Amplification kit (Ambion, Austin, USA). Microarray analysis was performed using Illumina SingleColor Human HT-12\_V3 Whole Genome Expression Chips (Illumina, San Diego, USA). All gene expression data are publically available (NCBI's Gene Expression Omnibus; Series Accession Number: GSE61376).

#### Data analysis

Quality control of microarray data involved examination of intensity histograms of hybridization efficiency and noise using BeadStudio, version 3 (Illumina, San Diego, USA). All subsequent analyses were performed using Genespring GX, version 12.6 (Agilent Technologies, Foster City, USA). Expression values were normalized to the median and 75th percentile. Values less than 0.01 were set to 0.01. The data were then filtered for significant signal on the basis of detection score ( $d \ge 0.95$ , which equates to a confidence value of  $P \leq 0.05$ ). At least 15 of 17 hybridizations had to pass these filtering criteria for a probe (gene) to be accepted. Analysis of variance (ANOVA,  $P \leq 0.05$  using Benjamini and Hochberg correction for multiple testing) identified genes whose expression differed between groups. Principle components analysis was used to examine the relatedness between groups. When multiple copies of the same gene are reported, this represents multiple probes to the same gene represented on the microarray platform. To further demonstrate the relationship between individual samples, clustering analysis was performed. This involved using the standard GeneSpring hierarchical clustering algorithm with the following settings and normalized intensity values: Euclidean distance metric, Ward's linkage rule and clustering on both entities (genes) and conditions (samples). A heatmap was compiled ranging from -2.0 as green to +2.0 as red, whereas black colouring indicated signal intensities close to the median control values.

#### Ingenuity pathway analysis (IPA)

IPA was used to identify diseases and biofunctions or canonical pathways that were over-represented by the differentially expressed genes (Jimenez-Marin *et al.* 2009). Network analysis was performed to create an overview of the main signalling processes occurring in the schistosome- or schistosome and hepatitis-affected liver. Up-stream regulator analysis was performed to identify common upstream factors (eg transcription factors or drugs) that could be regulating the observed response.

## Comparison with other hepatic diseases and a schistosome murine model

We compared our current findings with our previously published whole genome microarray analysis of a *S. japonicum* infection time course in C57 mice (Burke *et al.* 2010*b*). Additionally, a survey was performed of the literature and, more specifically, the NCBI website (http://www.ncbi.nlm.nih.gov) with complete GEO datasets (GDS) related to liver disease and disease models. Four additional datasets were selected including Alcoholic hepatitis (GDS4389), Concanavalin A-induced fulminant hepatitis model (GDS3752), Hepatitis B virus associated acute liver failure (GDS4387) and Hepatitis C Virus infection effect on Huh7 hepatoma cells (GDS4160). For all auxiliary datasets, intensity values were either presented as normalized to time point 0 for time course experiments or as fold changes relative to control tissues. Data were matched to the current results using either Gene Symbols or Gene Bank Accession Number for each feature.

Additional datasets used included Alcoholic hepatitis of *Homo sapiens* (Affo *et al.* 2013), concanavalin A (Con A) model analysis of Balb/C mice injected with ConA to induce fulminant hepatitis (Chen *et al.* 2010), Hepatitis B in an analysis of clinical samples (Nissim *et al.* 2012), and an analysis of human Huh7 hepatoma cells infected with Hepatitis C Virus and sampled at 6, 12, 18, 24 and 48 h post-infection (Blackham *et al.* 2010).

#### RESULTS

#### Patient parameters for selection in the study

We selected 17 liver biopsy samples for RNA isolation and subsequent microarray analysis. This subgroup consisted of 4 controls [C], 6 with schistosomiasis only [S], and 7 with schistosomiasis and viral hepatitis B [SH] histories. A summary of the clinical and histological features of these patients is presented in Table 1. The term 'Class' indicates the broad classification of samples into Control [C] with no features indicating hepatitis or schistosomiasis history, schistosomiasis [S] indicating a diagnosed schistosomiasis fibrosis grading and positive schistosomiasis history, and schistosomiasis/ hepatitis [SH] were patients presenting with both; schistosomiasis fibrosis grading and positive schistosomiasis history, and indications of a current (as antigen positive) or past hepatitis infection (antibody positive). 'ID' is a patient specific coding. 'Egg' indicates if the patient was positive or not for schistosome eggs in faecal samples by the Kato Katz diagnostic technique (Katz et al. 1972). 'HBV' is indicative of either antibodies or antigen to hepatitis B. 'Fibrosis Grade' was determined by ultrasound. 'Drinking History' of alcohol intake consisting of the weekly consumption of more than two standard drinks was noted, 'Sex' was coded and 'Age' recorded, 'Schisto history' and 'Schisto Treatment' indicates whether each patient was aware of a past schistosome infection and the number of praziquantel treatments he/she had received in the previous 5 years. 'Current HBV' due to hepatitis B infection was also noted.

$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	I able	1. Path(	ologica	1 able 1. Pathological features and clinical history of patient	of patients who	se liver biopsie	s were i	used If	ts whose liver biopsies were used in the microarray analysis	ınalysıs		
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Class <sup>a</sup>	$\mathrm{ID}^\mathrm{b}$	$\mathrm{Egg}^{\mathrm{c}}$	$HBV^{d}$	Fibrosis grade <sup>e</sup>	Enlarged liver <sup>f</sup>		${\rm Age}^{\rm h}$	Drinking history <sup>i</sup>	Schisto history <sup>j</sup>	Schisto treatment <sup><math>k</math></sup>	$Current HBV^{l}$
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	C	XY188	ND	None	$\mathbf{S1}$	Ι	1	19	+	I	None	Ι
C XY208 ND None S1 - 1 43 - None S1 - None S2 - 2 73 - None S2 - None S2 - 1 43 - None S2 - None S2 - 1 43 - None S2 - 1 1 43 - 1 None S2 + 1 2 54 - 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	с	XY204	ND	None	$\mathbf{S1}$	I	1	61	I	I	None	I
C XY215 - None S2 - 2 73 - None S2 - None S2 - 2 73 - None S2 - None S2 - 2 73 - None S2 - 1 - None S2 - 1 - 2 - None S2 - 1 - 2 - None S2 - 1 - 2 - 1 - 2 - 2 - 2 - 2 - 2 - 2 -	с	XY208	ND	None	$\mathbf{S1}$	I	1	43	I	I	None	I
S XY202 + None S4 + 2 52 - 7 + 3 S XY213 - None S2 + 1 2 54 - 7 + 1 S XY211 + None S2 + 2 35 - 7 + 1 S XY221 + None S2 + 2 36 - 7 + 2 S XY222 + None S2 + 1 60 - 7 + 2 S XY222 + None S2 + 1 60 - 7 + 2 S XY224 - HBsAb+; HBcAb+ S3 + 1 68 - 7 + 2 SH XY209 - HBsAg+, HBcAb+ S3 + 1 68 - 7 + 1 SH XY209 - HBsAg+, HBcAb+ S3 + 1 68 - 7 + 1 SH XY212 - HBsAg+, HBcAb+ S3 + 1 68 - 7 + 7 SH XY212 - HBsAg+, HBcAb+ S3 + 1 68 - 7 + 7 SH XY212 - HBsAg+, HBcAb+ S3 + 1 68 - 7 + 7 SH XY212 - HBsAg+, HBcAb+ S3 + 1 68 - 7 + 7 SH XY212 - HBsAg+, HBcAb+ S3 + 1 68 - 7 + 7 SH XY212 - HBsAg+, HBcAb+ S3 + 1 68 - 7 + 7 SH XY212 - HBsAg+, HBcAb+ S3 + 1 68 - 7 + 7 SH XY212 - HBsAg+, HBcAb+ S3 + 1 68 - 7 + 7 SH XY221 - HBsAg+, HBcAb+ S3 + 1 68 - 7 + 7 SH XY221 - HBsAg+, HBcAb+ S3 + 1 68 - 7 + 7 SH XY221 - HBsAg+, HBcAb+ S3 + 1 68 - 7 + 7 - 7 + 7 SH XY221 - HBsAg+, HBcAb+ S3 + 1 65 - 7 + 7 -	C	XY215	Ι	None	S2	I	2	73	I	I	None	I
S XY213 - None S2 + 2 54 - + 1 S XY211 + None S3 + 2 35 - + + 2 S XY211 + None S3 + 2 35 - + + 2 S XY222 + None S2 + 2 40 + + 2 S XY224 - None S3 + + 2 40 + + 2 SH XY207 - HBsAg+, HBcAb+, S3 + + 1 63 + + 2 SH XY212 - HBsAg+, HBcAb+, S3 + + 1 63 + + 2 SH XY212 - HBsAg+, HBcAb+, S3 + + 1 63 + + 2 SH XY212 - HBsAg+, HBcAb+, S3 + + 1 63 + + 2 SH XY212 - HBsAg+, HBcAb+, S3 + + 1 63 + + 2 SH XY212 - HBsAg+, HBcAb+, S3 + + 1 63 + + 2 SH XY212 - HBsAg+, HBcAb+, S3 + + 1 63 + + 2 SH XY212 - HBsAg+, HBcAb+, S3 + + 2 68 + + 2 SH XY221 - HBsAg+, HBcAb+, S3 + + 2 68 + + 2 SH XY221 - HBsAg+, HBcAb+, S3 + + 2 68 + + 2 SH XY221 - HBsAg+, HBcAb+, S3 + + 2 68 + + 2 SH XY221 - HBsAg+, HBcAb+, S3 + + 2 68 + + 2 SH XY221 - HBsAg+, HBcAb+, S3 + + 2 68 + + 2 SH XY221 - HBsAg+, HBcAb+, S3 + + 1 65 + + 2 SH XY221 - HBsAg+, HBcAb+, S3 + + 1 65 + + 2 SH XY221 - HBsAg+, HBcAb+, S3 + + 1 65 + + 2 SH XY221 - HBsAg+, HBcAb+, S3 + + 1 65 + + 2 SH XY221 - HBsAg+, HBcAb+, S3 + + 1 65 + + 2 SH XY221 - HBsAg+, HBcAb+, S3 + + 1 65 + + 2 SH XY222 - HBsAg+, HBcAb+, S3 + + 1 65 + + 2 SH XY221 - HBsAg+, HBcAb+, S3 + + 1 65 + + 2 SH XY221 - HBsAg+, HBcAb+, HBcAb+, S3 + + 1 65 + + 2 SH XY221 - HBsAg+, HBcAb+, HBcAb+, S3 + + 1 65 + + 2 SH XY221 - HBsAg+, HBcAb+, HBcAb+, S3 + + 1 65 + + 2 - 2 - + + 2 - 2 - + + 2 - 2 -	s	XY202	+	None	$\mathbf{S4}$	+	2	52	I	+	3	I
S XY182 + None S3 + 2 35 - + 2 S XY211 + None S2 + 1 60 - + 2 S XY221 + None S2 + 2 40 - + 2 S XY224 - None S3 + 2 36 - + 2 SH XY207 - HBsAg+, HBeAb+, S3 + 1 68 - + 1 SH XY209 - HBsAg+, HBeAb+, S3 + 1 68 - + 1 SH XY212 - HBsAg+, HBeAb+, S3 + 1 59 + + 1 SH XY212 - HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH XY214 + HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH XY214 - HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH XY214 - HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH XY214 - HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH XY214 - HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH XY221 - HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH XY221 - HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH XY221 - HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH XY221 - HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH XY221 - HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH SY221 - HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH SY221 - HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH SY221 - HBsAg+, HBeAb+ S3 + 1 59 + + 2 SH SY221 - HBsAg+, HBeAb+ S3 + 1 50 + + 2 SH SY221 - HBsAg+, HBeAb+ BAB+ S3 + 1 50 + + 2 SH SY221 - HBsAg+, HBeAb+ BAB+ S3 + + 1 50 + + 2 SH SY221 - HBsAg+, HBeAb+ BAB+ S3 + + 1 50 + + 2 SH SY221 - HBsAg+, HBeAb+ BAB+ S3 + + 1 50 + + 2 + 2 + 2 + 2 + 2 + 2 + 2 + 2 + 2	s	XY213	I	None	S2	+	2	54	I	+	1	I
S XY211 + None S2 + 1 60 - + 3 S XY222 + None S2 + 2 40 - + 2 + 2 S XY224 - None S3 + 2 36 - + 1 6 SH XY207 - HBsAb+; HBcAb+; S3 + 1 68 - + 1 6 SH XY209 - HBsAg+, HBcAb+, S3 + 1 63 - + 2 7 SH XY212 - HBsAg+, HBcAb+, S3 + 1 63 - + 2 7 SH XY212 - HBsAg+, HBcAb+, S3 + 1 63 - + 2 7 SH XY212 - HBsAg+, HBcAb+, S3 + 1 65 - + 2 7 SH XY221 - HBsAg+, HBcAb+, S3 + 1 65 - + 2 7 SH XY221 - HBsAg+, HBcAb+, S3 + 1 65 - + 2 68 - 1 + 2 68 - 1 + 2 68 - 1 + 2 68 - 1 + 2 68 - 1 + 1 65 - 1 + 1 1 65 - 1 + 1 1 1 65 - 1 + 1 1 1 65 - 1 + 1 1 65 - 1 + 1 1 1 65 - 1 + 1 1 1 65 - 1 + 1 1 1 65 - 1 + 1 1 1 65 - 1 + 1 1 1 65 - 1 + 1 1 1 65 - 1 + 1 1 1 65 - 1 + 1 1 1 1 65 - 1 + 1 1 1 1 65 - 1 + 1 1 1 1 65 - 1 + 1 1 1 1 1 65 - 1 + 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	s	XY182	+	None	$\mathbf{S3}$	+	2	35	I	+	2	I
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	s	XY211	+	None	S2	+	1	60	I	+	3	I
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	s	XY222	+	None	S2	+	2	40	I	+	2	I
SH XY207 - HBsAb+; HBcAb+; HBeAb+ S3 + 1 68 - + 1 SH XY209 - HBsAg+, HBeAb+, HBcAb+ S4 + + 1 63 - + 2 SH XY212 - HBsAg+, HBcAb+ S2 + + 2 54 - + 2 SH XY212 - HBsAg+, HBeAb+, HBcAb+ S3 + 1 59 + + 1 2 SH XY220 - HBsAg+, HBeAb+, HBcAb+ S3 + 1 59 + + 2 6 SH XY221 - HBsAg+ (HBcAb+ S3 + 1 37 + 1 65 - + 2 6 SH XY221 - HBsAg+ (HBcAb+ S3 + + 1 65 - + 2 6 SH XY221 - HBsAg+ (HBcAb+ S3 + + 1 65 - + 2 6 SH XY221 - HBsAg+ (HBcAb+ S3 + + 1 34 + 6 0 SH XY223 - HBsAg+ (HBcAb+ S3 + 1 34 + 6 0 SH XY223 - HBsAg+ (HBcAb+ S3 + 1 34 + 6 0 SH XY223 - HBsAg+ (HBcAb+ S3 + 1 34 + 6 0 SH XY223 - HBsAg+ (HBcAb+ S3 + 1 58) (Heratures indicating any prior hepatitis or schistosomiasis history; Schistosomia disease and S1-S4 represents the schistosomiasis fibrosis grading obtained by ultrasound; Schistosomiasis/Hepatitis B [SH] were patients presenting	s	XY224	Ι	None	$\mathbf{S3}$	+	2	36	I	+	0	I
SH XY209 - HBsAg+, HBeAb+, HBcAb+ S4 + $1 63 - + 2$ + 2 SH XY212 - HBsAg+, HbcAb+ S2 + $2 54 - + 2$ + 2 SH XY212 - HBsAg+, HBeAb+, HBcAb+ S3 + $1 59 + + 1$ + 2 SH XY220 - HBsAg+, HBeAb+, HBcAb+ S3 + $1 65 - + 2$ + 2 SH XY221 - HBsAg+ $2 68 - + + 2$ + 2 SH XY221 - HBsAg+ $3 - + 1 65 + 2$ + 2 SH XY223 - HBsAg+ $3 - + 1 34 + 2$	$\operatorname{HS}$	XY207	Ι	HBsAb+; HBcAb+; HBeAb+	$\mathbf{S3}$	+	1	68	I	+	1	+
SH XY212 - HBsÅg+, HbcAb+ S2 + 2 54 - + 2 54 - + 2 SH XY214 + HBsÅg+, HBcAb+ S3 + 1 59 + 1 + 1 6 + 1 8 SH XY220 - HBsÅg+, HBcAb+, HBcAb+ S3 + 1 65 - + 2 + 2 SH XY221 - HBsÅg+ BcAb+, HBcAb+ S3 + 1 65 - + 2 + 2 SH XY223 - HBsÅg+ 2 SH XY223 - HBsÅg+ 1 34 - + 1 34 + 1 $^{-3}$ Class shows the broad classification of samples into Control [C] with no features indicating any prior hepatitis or schistosomiasis history; Schistosomia disease and S1-S4 represents the schistosomiasis fibrosis grading obtained by ultrasound; Schistosomiasis/Hepatitis B [SH] were patients presenting	$\operatorname{HS}$	XY209	I	HBsAg+, HBeAb+, HBcAb+	$\mathbf{S4}$	+	1	63	I	+	2	+
SHXY214HBsAg+, HBcAb+, HBcAb+S3+159++1SHXY220-HBsAg+, HBcAb+, HBcAb+S3+165-++0SHXY221-HBsAg+HBcAb+S2+268-++2SHXY223-HBsAg+, HbcAb+S3+134-+2aClass shows the broad classification of samples into Control [C] with no features indicating any prior hepatitis or schistosomiasis history; SchistosomiaaClass shows the schistosomiasis fibrosis grading obtained by ultrasound; Schistosomiasis/Hepatitis B [SH] were patients presenting	$\operatorname{SH}$	XY212	I	HBsAg+, HbcAb+	S2	+	2	54	I	+	2	+
SH       XY220       HBsAg+, HBcAb+, HBcAb+       S3       +       1       65       -       +       0         SH       XY221       HBsAg+       HBsAg+       S2       +       2       68       -       +       2         SH       XY223       HBsAg+       HbcAb+       S3       +       1       34       -       +       2         a       Class shows the broad classification of samples into Control [C] with no features indicating any prior hepatitis or schistosomiasis history; Schistosomia       Schistosomiasis/Hepatitis B [SH] were patients presenting	HS	XY214	+	HBsAg+, HBeAb+, HBcAb+	$\mathbf{S3}$	+	1	59	+	+	1	+
SH       XY221       HBsAg+       S2       +       2       68       -       +       2         SH       XY223       HBsAg+, HbcAb+       S3       +       1       34       -       +       2         SH       XY223       HBsAg+, HbcAb+       S3       +       1       34       -       +       0	$\operatorname{SH}$	XY220	I	HBsAg+, HBeAb+, HBcAb+	$\mathbf{S3}$	+	1	65	I	+	0	+
SH       XY223       HBsAg+, HbcAb+       S3       +       1       34       -       +       0         -       -       -       S3       +       1       34       -       +       0         -       -       -       S3       +       1       34       -       +       0         -       -       -       -       S3       +       1       34       -       +       0         -       -       -       -       -       -       -       -       +       0         -       -       -       -       -       -       -       -       +       0         - <td><math>\operatorname{SH}</math></td> <td>XY221</td> <td>I</td> <td>HBsAg+</td> <td>S2</td> <td>+</td> <td>2</td> <td>68</td> <td>I</td> <td>+</td> <td>2</td> <td>+</td>	$\operatorname{SH}$	XY221	I	HBsAg+	S2	+	2	68	I	+	2	+
<sup>a</sup> Class shows the broad classification of samples into Control [C] with no features indicating any prior hepatitis or schistosomiasis history; Schistosomia disease and S1-S4 represents the schistosomiasis fibrosis grading obtained by ultrasound; Schistosomiasis/Hepatitis B [SH] were patients presenting	HS	XY223	Ι	HBsAg+, HbcAb+	$\mathbf{S3}$	+	1	34	I	+	0	+
tosomiasis fibrosis grading (S2-S4) and schistosomiasis history, and indications of a current (as antigen positive) or past (antibody positive) hepatitis infection.	<sup>a</sup> Class disease tosomi	s shows the and S1-S asis fibrosi	e broac 34 repre is grad	l classification of samples into Con- sents the schistosomiasis fibrosis ing (S2-S4) and schistosomiasis h	trol [C] with no fe grading obtained istory, and indica	atures indicating by ultrasound; S tions of a curren	any pric Schistosc tt (as ant	or hepai omiasis, tigen po	titis or schistosomia /Hepatitis B [SH] w ositive) or past (anti	sis history; Schisto vere patients prese body positive) he	osomiasis [S] indicate: enting with both dise: patitis infection.	s a history of the ases, with schis-

ID is the specific identification code for each patient.

ပ

Egg indicates whether the patient was faecal egg-positive or egg-negative by the Kato Katz technique. HBV is indicative of either antibodies or antigen to Hepatitis B, HBSAb+ (antibody positive for Hep B surface protein); HBCAb+ (antibody positive for Hep B core protein); HBeAb + (antibody positive for Hep B extracellular antigen).

Fibrosis grading determined by ultrasound.

σ

e

Presentation with an enlarged liver by ultrasound and by palpation. ÷

Sex is coded. ح 60

Age at time of liver biopsy.

<sup>i</sup> Drinking history of alcohol. j Schistosome infection history determined by questionnaire. <sup>k</sup> Schistosome treatment indicates if the patient was aware of a past schistosome infection and the number of praziquantel treatments they had received in the previous 5 years.

No patients were antibody positive for hepatitis C or D.

Samples were selected on the basis of clinical history and RNA quality (RIN  $\ge$  6) required to proceed to microarray analysis.

#### Transcriptional findings

Filtering of microarray data for the 17 samples commenced with the complete 48 803 probes contained within the microarray platform which were then filtered for flags (in at least 15/17 samples) thereby reducing the number to 20964. We then applied filters for detection score ( $d \ge 0.95$  equivalent of Pvalue  $\leq 0.05$ , in at least 15/17 samples), reducing the gene list to 12 611 probes, and then differential expression (1-way ANOVA with multiple testing correction  $P \leq 0.05$  (Benjamin-Hochberg), reducing the list to 3067 probes (online Supplementary Table 1). Of these 3067 probes, 1248 showed at least a ±2-fold change in expression in [S] and/or [SH] samples compared with the control [C] biopsy samples. Using the  $\pm 2$ -fold change cut-off, compared with [C], for [S], 12 genes were upregulated and 478 genes were downregulated, while for [SH] 52 genes were upregulated and 1167 genes were downregulated A total of 46 probes showed at least a 2-fold difference in expression between the [SH] and [S] groups. The relative transcriptional profiles of each of the samples are presented in Fig. 1; Control [C] samples were distinct from the other two disease groups (schistosomiasis only [S] and the combination schistosomiasis and hepatitis B [SH]) which had closer transcriptional profiles to each other. Principal components analysis (PCA) demonstrated that all of the [SH] samples clearly clustered together with three of the four [C] samples also clustering together. However, the [S] samples were divided between a close grouping with the [SH] samples (four samples), and two that were located between the [SH] and [C] groupings. The one outlier sample for [C] was from Patient ID XY204, who was older (61 years) than two of the other [C] samples but younger than the other (73 years). XY204 was the same sex as three other patients and could not be differentiated on the basis of drinking history or HBV status. Similarly the two outlier [S] samples (XY202, XY213) could not be separated by fibrosis grade, sex, age, drinking history, or schistosome treatment history. The diversity of the gene expression profiles demonstrated both control and diseased patients, shown in the PCA (Fig. 1) likely reflects the diversity of the clinical population sampled.

Hierarchical clustering of the 12611 genes was performed to further present the gene profiles of individual samples (Fig. 2). The outlier samples for each group identified earlier were again evident as were the similarities of the [S] and [SH] samples in




Fig. 1. Principal Component Analysis of the 17 liver biopsy samples utilizing 12 611 genes that passed quality control filtering. The controls [C] (stars), schistosomiasis [S] only patients (triangles) and the combination of schistosomiasis and hepatitis B [SH] (circles) are presented.

general. There was a clear general downregulation of genes of the disease samples (represented by the green colouration), whereas the upregulation of genes (in red) was less evident.

While different fibrosis grades were present with both the [S] and [SH] groups, comparisons between different grades was not possible due to the limited number of replicated samples available. This would be a useful approach for the future if larger numbers of samples can be obtained.

#### Ingenuity pathway analysis and keyword searches

Ingenuity pathway analysis of the 3067 identified genes by 1 way ANOVA for the [S] and [SH] groups revealed a similar functional profile (online Supplementary Table 2). Overall, the transcriptional profiles of these two patient cohorts were consistent with chronic liver disease of infectious aetiology in which significant immunomodulation has occurred. Over-represented biofunctions included 'protein synthesis', 'cell cycle' and 'energy metabolism'. The most prominent feature was identification of EIF2 (Eukaryotic Initiation Factor 2) signalling pathway as an enriched pathway for both [S] and [SH] (*P*-value  $6.6 \times 10^{-8}$ ), with key gene components downregulated in both disease groups when compared with controls. The downregulation of genes in this pathway and others associated with the 'protein synthesis' biofunction indicates likely impairment of protein synthesis in the liver of patients with [S] and/or [SH]. This is a common feature of chronic liver disease and is an indicator of reduced liver function (Krastev, 1998).

Most immune associated genes were downregulated or unchanged in both [S] and [SH] disease groups (See Table 2). There was no change in the expression of Th2 cytokines compared with controls while there was significant downregulation of IL-10 and IL18. Due to the immune-mediated nature of schistosome-induced pathology, we specifically

1457




Fig. 2. Heatmap of the hierarchical clustering of all 17 liver biopsy samples utilizing 12 611 genes that passed quality control filtering. The controls [C], schistosomiasis [S] only patients and the combination of schistosomiasis and hepatitis B [SH] are presented. The patient ID is also included to allow cross-referencing with Table 1. Gene intensities normalized to controls are shown, ranging from downregulated to -2.0 in green, upregulated to 2.0 in red, with control intensities shown in black.

examined the expression of genes associated with 'inflammation' and 'immune responses' using IPA keyword based searches. Genes associated with inflammation are presented in Table 3 and generally were downregulated in the [S] and [SH] samples. In a murine model of acute hepatic schistosomiasis japonica (Burke *et al.* 2010*b*) (up to 7 weeks post cercarial challenge) none of these genes were generally differentially expressed, with the exception of IL10 which approached upregulation at 1·9-fold. A set of three genes associated with granulocytes, MMP7, CLDN7 and CXCL6 ([S] 1·55, 1·54, 1·55, [SH] 3·21, 2·17, 2·04), were upregulated in [SH] samples, but a lower level of upregulation, less than a 2-fold cut-off, was noted for the [S]

samples. Similarly, functions and genes related to the extracellular matrix (FERMT2, SDC2 and VHL, [S]: -2.20, -1.96, -1.61; [SH] -3.23 -3.02-2.19) were downregulated in both the [S] and [SH] disease groups, as were genes associated with connective tissue cells (Table 4). Antiviral genes IFITM1 (1.4, -1.7) and MX1 (1.2, -1.9) were also identified in annotation searches and were differentially expressed in [S] and [SH] patients.

#### Comparison of [S] and [SH] profiles

Final interrogation of the transcriptional dataset was undertaken to differentiate between [S] and [SH] patients. This involved consideration of all

Table 2.	Immune associated	l genes, identified from	n genes shown to	) be differentially e	expressed using k	xeyword
searches f	for 'interleukin', 'cl	hemokine', 'cytokine'	, 'interferon' or	'tumour necrosis	factor'	

C	Description	Fold cha	ange	
Gene	Description	[S] vs [C]	[SH] vs [C]	[S] vs [SH]
CCL23	Chemokine (C-C motif) ligand 23, transcript variant CKbeta8.	-1.44	-2.09	1.45
CCL28	Chemokine (C-C motif) ligand 28, transcript variant 1.	1.17	1.44	-1.23
CCR6	Chemokine (C-C motif) receptor 6, transcript variant 2.	-1.87	-2.73	1.46
CX3CL1	Chemokine (C-X3-C motif) ligand 1.	-1.43	-2.41	1.69
CXCL12	Chemokine (C-X-C motif) ligand 12, transcript variant 2.	-1.51	-1.76	1.17
CXCL14	Chemokine (C-X-C motif) ligand 14.	-2.34	-2.44	1.04
CXCL6	Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2).	1.47	2.33	-1.58
CXCL6	Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein 2).	1.55	2.04	-1.32
CIP29	Cytokine induced protein 29 kDa.	-1.74	-1.84	1.06
CRLF3	Cytokine receptor-like factor 3.	-1.46	-1.33	-1.1
IFITM1	Interferon induced transmembrane protein 1 (9–27).	1.36	-1.71	2.33
IRF2	Interferon regulatory factor 2.	1.51	1.82	-1.2
IRF2BP2	Interferon regulatory factor 2 binding protein 2; transcript variant 1.	-1.28	-1.78	1.39
ISG20L2	Interferon stimulated exonuclease gene 20 kDa-like 2.	-1.06	-1.37	1.3
IFNA8	Interferon, alpha 8.	-1.33	-1.37	1.02
IFIT1	Interferon-induced protein with tetratricopeptide repeats 1, tran- script variant 2.	-1.23	-2.1	1.71
IFIT2	Interferon-induced protein with tetratricopeptide repeats 2.	-1.69	-2.22	1.32
IFRD1	Interferon-related developmental regulator 1, transcript variant 1.	-1.81	-2.04	1.13
IL10	Interleukin 10.	-2.13	-3.62	1.7
IL10RB	Interleukin 10 receptor, beta.	-1.97	-2.9	1.47
IL15	Interleukin 15, transcript variant 3.	-1.29	-1.37	1.07
IL17RD	Interleukin 17 receptor D, transcript variant 1.	-2.22	-2.87	1.29
IL18	Interleukin 18 (interferon-gamma-inducing factor).	-1.9	-2.5	1.31
IL18	Interleukin 18 (interferon-gamma-inducing factor)).	-1.9	-2.5	1.31
IRAK1	Interleukin-1 receptor-associated kinase 1; transcript variant 3.	-1.48	-1.75	1.18
MX1	Myxovirus (influenza virus) resistance 1, interferon-inducible protein p78 (mouse).	1.5	-1.89	2.25
PRKRA	Protein kinase, interferon-inducible double stranded RNA dependent activator.	-2.15	-2	-1.07
TGIF1	TGFB-induced factor homeobox 1, transcript variant 1.	1.26	1.56	-1.24
TGIF2	TGFB-induced factor homeobox 2.	-1.04	-1.36	1.31
TGFBRAP1	Transforming growth factor, beta receptor associated protein 1.	-1.25	-1.33	1.06
TGFBR2	Transforming growth factor, beta receptor II (70/80 kDa), transcript variant 1.	$-2\cdot 2$	-2.71	1.23
TNFSF13B	Tumour necrosis factor (ligand) superfamily, member 13b.	-1.47	-1.84	1.25
TNFSF14	Tumour necrosis factor (ligand) superfamily, member 14), transcript variant 2.		-3.08	2.35
TNFRSF1B	Tumour necrosis factor receptor superfamily, member 1B.	-1.42	-2.17	1.53
TNFAIP2	Tumour necrosis factor, alpha-induced protein 2.	1.16	1.63	-1.4

Fold change is presented as schistosomiasis only [S] or schistosomiasis and viral hepatitis B [SH] relative to controls [C], and schistosomiasis only [S] relative to schistosomiasis and viral hepatitis B [SH].

differentially expressed genes with a  $\pm 2$ -fold change between the two disease groups [S] and [SH], which yielded 46 candidates (online Supplementary Table 1). No genes were upregulated in one group and downregulated in the other by more than the  $\pm 2$ -fold cut-off. Correlation of the two groups generally presented a high degree of similarity with r = 0.85(*P* value <0.0001) (Fig. 3). For example, TSPAN33 (tetraspanin 33), which ensures normal erythropoiesis, through the differentiation of progenitor cells (Heikens *et al.* 2007), was downregulated in both samples although downregulation of the gene was more pronounced in [S] (-1.73-fold) than in [SH] (-3.9-fold). Other examples included genes such as TACSTD1, LEPR, UBD, LGALS4 and FXYD2, which were moderately up-regulated in the [S] group (1.2-2.6-fold) but exhibited increased upregulation in the [SH] group (4.3-6.1-fold). Similarly, genes that were downregulated in the [S] group, such as RPS15A, NDUFB10, BLVRB and PCOLCE2 (-2.5 to -2.8-fold), were more downmodulated in the [SH] group (-5.7 to -7.3-fold)

In general, when normalized to controls [C] enrichment of disease, biofunctions and canonical

			Fold cha	nge	
Diseases or function	<i>P</i> -value	Genes	[S] vs [C]	[SH] <i>vs</i> [C]	[S] <i>vs</i> [SH]
Immune response of Th1 cells.	$5.16 \times 10^{-3}$	ETS1 HAVCR2 IL10 IL18	-2.2 -1.3 -2.1 -1.9	-2.5 -2 -3.6 -2.5	$     \begin{array}{r}       1 \cdot 2 \\       1 \cdot 5 \\       1 \cdot 7 \\       1 \cdot 3     \end{array} $
Cytotoxic reaction of pancreatic cancer cell lines.	$2 \cdot 10 \times 10^{-2}$		-1.5 -1.2	-1.3	-1.2 1.3
Endotoxin tolerance of bone marrow-derived macrophages.	$2 \cdot 10 \times 10^{-2}$	SMAD4	-1.6	-1.8	1.1
Induction of monocyte-derived dendritic cells.	$2 \cdot 10 \times 10^{-2}$	TSC1 IL10 IL15	-2.4 -2.1 -1.3	$-3.2 \\ -3.6 \\ -1.4$	1·3 1·7 1·1
Activation of TREG cells.	$2.97 \times 10^{-2}$	CD2 ETS1 IL10	$1 -2 \cdot 2 -2 \cdot 1$	1.7 - 2.5 - 3.6	-1.7 $1.2$ $1.7$
Enterocolitis.	$3.01 \times 10^{-2}$	IL10RB MAP3K5	-1.5 -1.6 -2.1 -2 -1.4	-2.9 -1.6	$ \begin{array}{c} 2 \cdot 1 \\ 1 \cdot 2 \\ 1 \cdot 7 \\ 1 \cdot 5 \\ 1 \cdot 2 \end{array} $
		MAP3K5 STAT3	-1.4 $1.8$	-1.6 2.4	$1 \cdot 2$ $-1 \cdot 4$

Table 3. Diseases or functions annotation associated with 'Inflammation' identified by Ingenuity Pathway Analysis of the 3065 differentially expressed genes

Fold change is presented as schistosomiasis only [S] or schistosomiasis and viral hepatitis B [SH] relative to controls [C], and schistosomiasis only [S] relative to schistosomiasis and viral hepatitis B [SH].

pathways were more pronounced in the [SH] group compared with the [S] group. Increased downregulation of genes associated with, for example, EIF2 Signalling (*P*-value 1.58E-13), Protein Ubiquitination  $(3.09 \times 10^{-8})$ , Regulation of eIF4 and p70S6K Signalling  $(2.45 \times 10^{-7})$ , and mTOR Signalling (*P* value  $1.02 \times 10^{-6}$ ) (online Supplementary Table 2). This suggests that liver function was more compromised in the [SH] compared with the [S] patients a feature consistent with the increased pathology in this group of patients.

Ubiquitin has been reported as a biomarker for non-alcoholic Steatohepatitis (NASH) in humans (Banner *et al.* 2000). The identification of Post-Translational Modification: 'ubiquitination of protein' from IPA (*P*-value  $1.92 \times 10^{-7}$ ) showed that almost all of the 68 genes in the pathway were moderately downregulated in both the [S] and [SH] groups with only UBD (ubiquitin D) being upregulated 1.8-fold for [S] and 4.8-fold for [SH] (See online Supplementary Tables 1 & 2).

The most upregulated gene in [S] patients was IGFBP2 (6.9-fold) and this was also upregulated in [SH] but to a lesser extent (3.8-fold).

### Comparison with the mouse model of schistosomiasis japonica

A comparison of the transcriptional profiles of human hepatic schistosomiasis and our previously

published study of acute S. japonicum infection in the livers of C57 BL/6 mice (Burke et al. 2010b) indicated few similarities. Of the 3067 differentially expressed genes in the human samples, 1625 were also differentially expressed in the mouse model (Burke et al. 2010b). A Spearman's correlation of expression of these genes in the [S] or [SH] samples compared with the livers from mice 7 weeks post cercarial challenge (the latest time point analysed) produced an  $R^2$  of [S]/C57 = 0.1 (P value <0.001) and [SH]/C57 = 0.07 (P value = 0.0034) (Fig. 4). A subset of genes did show similar gene expression levels in human hepatic and murine schistosomiasis (online Supplementary Table 3). Genes that were: upregulated in both [S] and mice (0 genes), upregulated in both [SH] and mice (3 genes, UBD, PITPNM1, SOX9, see Table 4), downregulated in both [S] and mice (54 genes) and downregulated in both [SH] and mice (109 genes). Common genes that were downregulated in [S] and [SH] compared with [C], and also downregulated in murine schistosomiasis included those associated with fatty acid metabolism (ACSL1, ALDH6A1, DCI, HADHB and ACAA2), vesicle transport (VTI1B), and proinflammatory IL18, the only gene related to immunology.

#### Comparison with other hepatic diseases

Distinct differences were apparent on comparing transcriptional responses demonstrated in the

		Fold ch	ange	
Category and gene	Gene description	[S] <i>vs</i> [C]	[SH] vs [C]	[S] <i>vs</i> [SH]
Proliferation of	connective tissue cells.			
ADAR	Adenosine deaminase, RNA-specific.	-2.1	-2.8	1.3
BCL2L2	BCL2-like 2.	-2.4	-3	1.2
BMI1	BMI1 polycomb ring finger oncogene.	-2.1	-2.5	1.2
CCNG1	Cyclin G1.	-3.3	-4.4	1.4
CDK6 GHR	Cyclin-dependent kinase 6. Growth hormone receptor.	$-2 \cdot 2 \\ -2 \cdot 2$	-1.9 -2.7	$-1.1 \\ 1.2$
HTR2A	5-hydroxytryptamine (serotonin) receptor 2A.	-2.5 -2.6	-2.9	1.2
IGFBP5	Insulin-like growth factor binding protein 5.	-2.0 -4	-2.9 -4.8	1.2
IL10	Interleukin 10.	-2.1	-3.6	$1.2 \\ 1.7$
LEP	Leptin (obesity homolog, mouse).	-2.3	-3.7	1.6
LEPR	Leptin receptor.	2.5	5.2	-2
MAP3K1	Mitogen-activated protein kinase kinase kinase 1.	$-2^{-2}$	-2.3	1.1
MCM8	Minichromosome maintenance complex component 8.	-2.6	-5	1.9
MORF4L1	Mortality factor 4 like 1.	-2	-2.3	1.1
NDUFS4	NADH dehydrogenase (ubiquinone) Fe-S protein 4.	-2.1	-2.7	1.3
NOTCH1	Notch homolog 1, translocation-associated (Drosophila).	-2	-3.4	1.7
NUPR1	Nuclear protein 1.	-1.9	-2.3	1.2
PDGFC	Platelet derived growth factor C.	-2.1	-2.6	1.3
PRKAA1	Protein kinase, AMP-activated, alpha 1 catalytic subunit.	-2.8	-3.4	1.2
PTPRF	Protein tyrosine phosphatase, receptor type, F.	-2.8	-4.5	1.6
SERPINF1	Serpin peptidase inhibitor, clade F.	-2.4	-3.9	1.6
SMAD6	SMAD family member 6.	-2.1	-2.5	1.2
TFG TGFBR2	TRK-fused gene.	$-2.1 \\ -2.2$	$-2 \cdot 2 \\ -2 \cdot 7$	1 1·2
	Transforming growth factor, beta receptor II (70/80 kDa).	$-2 \cdot 2$ $-5 \cdot 1$	-2.7 -7.8	$1 \cdot 2$ $1 \cdot 5$
TXNIP YBX1	Thioredoxin interacting protein.	-3.1 -2.3	-2.8	1.5
YY1	Y box binding protein 1. YY1 transcription factor.	-1.9	-2.3	1.2
	thesion and Diapedesis/Leukocyte Extravasation Signalling	-1 )	-2 3	1 2
MMP7	Matrix metallopeptidase 7 (matrilysin, uterine).	1.55	3.21	-2.07
CLDN7	Claudin 7.	1.54	2.17	-1.41
CXCL6	Chemokine (C-X-C motif) ligand 6 (granulocyte chemotactic protein	1.55	2.04	-1.32
	2).			
Apoptosis of Lo		0.04	2 52	4.00
ETS2	v-ets erythroblastosis virus E26 oncogene homolog 2 (avian).	2.21	2.72	-1.23
LEPR	Leptin receptor, transcript variant 2.	2.55	5.22	-2.05
LGALS4	Lectin, galactoside-binding, soluble, 4 (galectin 4).	1.41	4·3	-3.04
STAT3 Hanatia Stanali	Signal transducer and activator of transcription 3.	1.78	2.41	-1.35
Hepatic Sterolis ACACA	Acetyl-Coenzyme A carboxylase alpha, transcript variant 3.	-2.78	-2.69	1.03
CAT	Catalase.	-3.11	-2.09 -4.09	-1.03 1.31
DECR1	2,4-dienoyl CoA reductase 1, mitochondrial.	-3.88	-4.69	1.21
GHR	Growth hormone receptor.	-2.19	-2.71	1.24
IL10	Interleukin 10.	-2.13	-3.62	1.7
LEP	Leptin (obesity homolog, mouse).	-2.29	-3.65	1.59
NR1H3	Nuclear receptor subfamily 1, group H, member 3.	-2.6	-4.97	1.91
PDE3B	Phosphodiesterase 3B, cGMP-inhibited.	-2.02	-1.33	-1.53
PDGFC	Platelet derived growth factor C.	-2.07	-2.6	1.25
PNRC2	Proline-rich nuclear receptor coactivator 2.	-2.1	-2.61	1.24
POR	P450 (cytochrome) oxidoreductase.	2.26	2.61	-1.15
PTPN11	Protein tyrosine phosphatase, non-receptor type 11.	-2.68	-3.03	1.13
TSC22D3	TSC22 domain family, member 3.	-2.23	-2.54	1.14
TXNIP	Thioredoxin interacting protein.	-5.13	-7.76	1.51
	position and extracellular matrix.	2.2	2.22	4 A =
FERMT2	Fermitin family homolog 2 (Drosophila).	-2.2	-3.23	1.47
SDC2	Syndecan 2.	-1.96	-3.02	1.54
VHL Homo Dogrado	Von Hippel-Lindau tumour suppressor, transcript variant 2.	-1.61	-2.19	1.36
Heme Degrada BLVRA	Biliverdin reductase A.	-2.24	-2.52	1.12
BLVRB	Biliverdin reductase A. Biliverdin reductase B (flavin reductase (NADPH).	-2.24 -2.77	-2.32 -5.73	2.07
Lipids		2 , ,	515	2 07
-r				

Table 4. Differentially expressed genes of novel biological functions selected from Ingenuity Pathway Analysis

Table 4. (Cont.)

Geoffrey N. Gobert and others

Category and gene	Gene description	[S] vs [C]	[SH] vs [C]	[S] <i>vs</i> [SH]
ACACA	Acetyl-Coenzyme A carboxylase alpha, transcript variant 3.	-2.78	-2.69	-1.03
ACSL1	Acyl-CoA synthetase long-chain family member 1.	-2.86	-4.38	1.53
CXCL14	Chemokine (C-X-C motif) ligand 14.	-2.34	-2.44	1.04
DBI	Diazepam binding inhibitor (GABA receptor modulator, acyl-	-1.53	-1.74	1.14
	Coenzyme A binding protein), transcript variant 2.			
DGAT2	Diacylglycerol O-acyltransferase homolog 2 (mouse).	-2.84	-4.13	1.46
GHR	Growth hormone receptor.	-2.19	-2.71	1.24
GPAM	Glycerol-3-phosphate acyltransferase, mitochondrial.	-5.23	-7.2	1.38
IL10	Interleukin 10.	-2.13	-3.62	1.7
LEP	Leptin (obesity homolog, mouse).	-2.29	-3.65	1.59
LEPR	Leptin receptor, transcript variant 2.	2.55	5.22	-2.05
MLXIPL	MLX interacting protein-like, transcript variant 3.	-2.25	-5.12	2.28
NR1H3	Nuclear receptor subfamily 1, group H, member 3.	-2.6	-4.97	1.91
PDE3B	Phosphodiesterase 3B, cGMP-inhibited.	-2.02	-1.33	-1.53
PIK3R1	Phosphoinositide-3-kinase, regulatory subunit 1 (alpha), transcript	-2.26	-2.79	1.24
	variant 1.			
POR	P450 (cytochrome) oxidoreductase.	2.26	2.61	-1.15
PRKAA1	Protein kinase, AMP-activated, alpha 1 catalytic subunit, transcript variant 2.	-2.77	-3.41	1.23
PTPN11	Protein tyrosine phosphatase, non-receptor type 11 (Noonan syndrome 1).	-2.68	-3.03	1.13
THRSP	Thyroid hormone responsive (SPOT14 homolog, rat).	-3.3	-4.46	1.35
TXNIP	Thioredoxin interacting protein.	-5.13	-7.76	1.51

Fold changes are presented as schistosomiasis only [S] or schistosomiasis and viral hepatitis B [SH] relative to controls [C], and schistosomiasis only [S] relative to schistosomiasis and viral hepatitis B [SH]




Fig. 3. Correlation between the relative fold changes for 3067 genes of schistosomiasis only [S] samples (x-axis) compared with schistosomiasis and viral hepatitis B [SH] samples (y-axis) relative to control samples. A  $\pm 2$ -fold change is marked with a dotted line and used to identify genes with a similar differential expression patterns between the [S] and [SH] sample groups. The linear regression is plotted with an  $R^2 = 0.85$  and P value <0.0001.

schistosomiasis datasets to other human hepatic diseases. The transcriptional profiles of genes that were upregulated in either [S] or [SH] were compared with other hepatic disease datasets (see Table 5). For example, the neutrophil chemokine CXCL6 (upregulated 1.5 to 2.3-fold in [S] or SH) is downregulated in HCV (-2.5-fold) and Con A (-2.4-fold) disease states, but is upregulated in Alcohol (2.2). MMP7 was upregulated in [S] and [SH] (1.4-3.2-

fold) to a similar extent compared with some other hepatic diseases examined (up-regulated in HBV, 2.0-fold; Con A,1.7-fold; and alcohol,2.6-fold). In addition a further 283 genes that were downregulated in [S] or [SH], compared with normal controls [C] are presented in online Supplementary Table 4. Of these downregulated genes, some (see online Supplementary Table 4 and Table 5) were related to Ribosome Function (MRPL13, RPL21, RPL23, RPL3, RPS15, RPS15A, RPS16, RPS3A), Fatty Acid Metabolism (ACSL1, ALDH3A2, DCI, HADHB, ACAA2) and Glycolipid Function (AGPAT2, ALDH3A2, DGAT2, GPAM). The downregulation of these genes is not mirrored in other hepatic diseases (HBV, HCV, Con A and Alcohol) examined (See online Supplementary Table 4) but has been observed in murine models of schistosomiasis reported by our group (Burke et al. 2010b).

We compared our data with those obtained by Nissim and colleagues (Nissim et al. 2012) who examined the gene profile of clinical cases of acute liver failure attributed to HBV. A number of genes in the [S] and/or [SH] patients correlated with genes up or downregulated in the HBV study (online Supplementary Table 4). Some downregulated genes in the [S] subjects were more downregulated in [SH], similar to the pattern of downregulated genes reported by Nissim et al.

Fold change




Fig. 4. Correlation between the relative fold changes of *schistosomiasis japonica* [S] (left) or schistosomiasis and viral hepatitis B [SH] (right) liver biopsy samples on the *y*-axis and C57 (7 weeks post cercarial challenge from (Burke *et al.* 2010*b*)) on the *x*-axis, for 1625 genes. Regions of similar gene expression are boxed; a  $\pm 2$ -fold change is marked with a dotted line and used to identify genes with a similar expression pattern in the human and murine studies.

(2012), possibly reflecting the differences between the [S] and [SH] patients. These genes included (fold change [S]|[SH]|HBV): cysteine dioxygenase, type I (CDO1; -2.17|-3.17|-1.71); thyroid hormone responsive (THRSP; -3.30|-4.46|-1.67); procollagen C-endopeptidase enhancer 2 (PCOLCE2; -2.46|-7.32|-1.64); aldehyde dehydrogenase 6 family, member A1 (ALDH6A1; -3.37|-5.10|-1.47); and growth hormone receptor (GHR; -2.19|-2.71|-1.45). These genes represent biological function related to metabolism, tissue remodelling and hormone regulation, While a small number of genes were upregulated in the HBV study could contribute to upregulation seen in our [S] and to a great extent [SH], these included the tissue remodelling gene matrix metallopeptidase 7 (MMP7; 1.55|3.21|2.05), and chemokine (C-X-C motif) ligand 6 (CXCL6; 1.55 | 2.04 | 1.71).

#### DISCUSSION

Pathway analysis and gene ontology analysis of moderately differentially expressed genes presented in either in [S] or [SH] patients compared with controls, demonstrated many potentially important biological functions reflecting the transcriptional profile of human hepatic schistosomiasis. Data generated from murine schistosomiasis studies are generally obtained from short-term acute infections, of 2-3 months duration only. This is direct contrast to the results obtained here from a clinical cohort with patients having been infected/cured multiple times over a long period, in some instances, up to several years at a time. Consequently, direct comparisons between experimental murine schistosomiasis and the natural progression of the human disease are problematical and somewhat artificial but the current study emphasizes the value and novelty of the clinical data we describe. The limitations and difficulties in undertaking animal studies for extended periods make progress in our understanding of chronic hepatic schistosomiasis challenging.

mTOR signalling (mechanistic target of rapamycin) was one of the prominent pathways identified from examination of differentially expressed genes in the livers of schistosomiasis only [S] or schistosomiasis and viral hepatitis B [SH] patients, compared with controls [C]. It is known that mTOR signalling regulates basic metabolic functions in the liver and is disrupted in both metabolic (diabetes, obesity) and non-metabolic (aging, neurodegeneration, cancer) disease states in a wide range of tissues (Laplante and Sabatini, 2012). Furthermore, mTOR signalling is significant in promoting fibrosis via macrophages and myofibroblasts in both kidney and intestinal tissues (Whaley-Connell et al. 2011; Chen et al. 2012; Jiang et al. 2013). Therefore, in our study it is noteworthy that in [S] and even [SH] patients, with a history of both viral hepatitis B and schistosomiasis, this pathway was depressed, with 45 of 50 genes in the pathway downregulated, which may reflect a lack of active gene transcription for fibrosis in these chronic [S] and [SH] patients. This is in direct contrast to reports of the upregulation of mTOR in the livers of subjects with both hepatitis C (Bose et al. 2012) and hepatitis B (Yen et al. 2012), and the correlation of this elevated expression with the increased likelihood of hepatocellular carcinoma (Wang et al. 2014). In this respect, it has been suggested that the risk of hepatocellular carcinoma development is elevated in chronic schistosomiasis associated with HBV infection, compared with HBV infections solely (Ross et al. 2002). A possible mechanism explaining the downregulation of the mTOR pathway in the current study could involve the upregulation of DNA damage response genes, such as caspase 9 (CASP9, [S] 1.2-fold, [SH] 1.5fold), or genes associated with oxidative stress such as FXYD2 (FXYD domain containing ion transport regulator 2) and POR (P450 (cytochrome) oxidoreductase) (See Table 5), as well as the reduction in gene expression of multiple ATPases (Adenosine triphosphate) and ATP synthases (see online Supplementary Table 1). It is known that reduced metabolism, leading to reduced ATP levels and increased hypoxia and DNA damage causes constitutive downregulation of the PI3K-mTORC1 axis

		Fold change	ange					(Fold range Min–Max)	[ax)
Symbol	Definition	[S] <i>vs</i>	[SH] <i>vs</i> [C]	[HS] <i>vs</i>	C57 (Weeks: 4,6,7)	HBV	Alcohol	HCV	CON A
ACAA2 ACSL1	Acetyl-Coenzyme A acyltransferase 2. Acyl-CoA synthetase long-chain family	$-2.91 \\ -2.86$	-3.64 -4.38	$\begin{array}{c} 1\cdot 25\\ 1\cdot 53\end{array}$	$-1 \cdot 1, -1 \cdot 9, -2 \cdot 6$ $-2 \cdot 1, -3 \cdot 8, -6 \cdot 6$	-1.02 -1.16	-1.02 -1.02 -1.05	-1.3 to $1.0-1.5$ to $2.6$	$1-1 \cdot 1$ 1 to -1 $\cdot 9$
AGPAT2	member 1. 1-acylglycerol-3-phosphate O-acyltransfer-	-1.85	-2.69	1.46	$-1 \cdot 4, -1 \cdot 1, -1 \cdot 6$	#N/A	$1 \cdot 04$	$-1 \cdot 3$ to $1 \cdot 0$	#N/A
ALDH3A2	ase 2. Aldehyde dehydrogenase 3 family, member ^^	-1.87	-2.1	$1 \cdot 12$	-1.8, -5.1, -7	#N/A	$1 \cdot 02$	-1.6 to 1.2	#N/A
ALDH6A1	A.C. Aldehyde dehydrogenase 6 family, member A1	-3.37	-5.1	1.51	-4.3, -3.9, -10.5	$-1 \cdot 47$	-1.11	$1 \cdot 1 - 1 \cdot 2$	1 to $-2.0$
ATXN2L CCR6	Ataxin 2-like, transcript variant A. Chemokine (CC morif) recentor 6.	1.87 - 1.87	2.1 - 2.73	-1.2 1.46	#N/A 1+2_1+2_1+3	$1 \cdot 08$	1·02 #N/A	-1.03 to $2.113.2$ to $-1.1$	-2.69 to $-1.141.0$ to $-4.2$
CXCL12	Chemokine (C-X-C motif) ligand 12.	-1.51	-1.76	1.17	$1 \cdot 0, -1 \cdot 1, 1 \cdot 0$	1.1	1	$1 \cdot 0 - 1 \cdot 1$	-1.1 to $-1.5$
CXCL6	Chemokine (C-X-C motif) ligand 6.	1.5	2.3	-1.6	#N/A	1.71	2.23	-2.53  to  -1.22	-2.4  to  -1.91
CXCL6	Chemokine (C-X-C motif) ligand 6.	1.6 2.02	2.0 2	-1.3	#N/A	1·71	2·23	-2.53  to  -1.22	-2.4  to  -1.91
DGAT2	Douecenoy1-Coenzyme A delta isomerase. Diacylglycerol O-acyltransferase homolog 2.	-2.00 -2.84	-5.52 -4·13	1.01	-1.9, -3.3, -3.4 -2.6, -2, -3.6	A/N#	#1N/A -1·21	+10/A -1.4 to 1.2	AN/A
FXYD2	FXYD domain containing ion transport	$1\cdot 2$	4.3	-3.5	-1.0, -1.2, -1.3	1.41	$1 \cdot 4$	$-1 \cdot 1$ to $-1 \cdot 02$	1.29-2.76
GPAM	regulator 2. Glycerol-3-phosphate acyltransferase.	-5.23	-7.2	1.38	-1.3, $-1.4$ , $-1.6$	#N/A	-1.02	1.6-2.8	#N/A
HADHB	Hydroxyacyl-Coenzyme A dehydrogenase.	-2.91	-2.88	-1.01	-1.1, -1.5, -2.5	-1.04	$1 \cdot 03$	$1 \cdot 0 - 1 \cdot 2$	1  to  -1.5
IGFBP2	Insulin-like growth factor binding protein 2, 36 PDa	6.9	3.8	$1 \cdot 8$	-2.5, -5.7, -4.2	-1.39	$-1 \cdot 0$	-1.06 to $1.17$	1.22 - 4.83
IL18	Interleukin 18 (interferon-gamma-inducing	-1.9	-2.5	$1 \cdot 31$	-1.5, -1, -2.1	1.62	$1 \cdot 50$	-1.5 to $1.0$	$1 \text{ to } -1 \cdot 2$
MMP7	Tactor). Matrix metallopeptidase 7 (matrilysin,	1.6	3.2	-2.1	$-1 \cdot 2, -1 \cdot 1, -1 \cdot 1$	2.05	2.61	-1.1  to  1.01	-1.37 to $1.71$
MMP7	uterne). Matrix metallopeptidase 7 (matrilysin,	1.4	2.6	-1.8	$-1 \cdot 2, -1 \cdot 1, -1 \cdot 1$	2.05	2.61	-1.1  to  1.01	-1.37 to $1.71$
PACS1	uterme). Phosphofurin acidic cluster sorting protein 1.	1.7	2.3	-1-4	1.3, 1.6, 1.5	$1 \cdot 07$	$1 \cdot 00$	-1.36 to 2.2	-2.74 to $-1.53$

1464

PHLDA1	Pleckstrin homology-like domain, family A,	4.3	4.5	$-1 \cdot 1$	-2.8, -3.3, -4.1	$-1 \cdot 0$	$-1 \cdot 17$	$1 \cdot 42 - 4 \cdot 35$	-2.44  to  -1.31
PITPNM1 POR SHB	Phosphatidylinositol transfer protein. P450 (cytochrome) oxidoreductase. Src homology 2 domain containing adaptor	$\begin{array}{c} 1\cdot 9\\ 2\cdot 3\\ 1\cdot 7\end{array}$	2.8 2.5	$\begin{array}{c} -1 \cdot 5 \\ -1 \cdot 2 \\ -1 \cdot 3 \\ -1 \cdot 3 \\ \end{array}$	$\begin{array}{c} 3\cdot 1, \ 5\cdot 2, \ 5\cdot 1\\ -1\cdot 9, \ -1\cdot 6, \ -1\cdot 7\\ -1\cdot 2, \ -1\cdot 1, \ -1\cdot 3\end{array}$	1.04 #N/A 1.01	$\begin{array}{c} -1 \cdot 00 \\ \# N/A \\ 1 \cdot 21 \end{array}$	-1.98 to $1.09-1.32$ to $1.11-1.11$ to $1.06$	-1.24 to 1.18 -1.19 to 2.93 -1.07 to 2.07
SOX9 TMPRSS2 UBD VT11B	protein B. SRY (sex determining region Y)-box 9. 1.1 Transmembrane protease, serine 2. 2.1 Ubiquitin D. 1.8 Vesicle transport through interaction with t1.8 SNAREs homolog 1B	$1 \cdot 1$ $2 \cdot 1$ $-1 \cdot 8$ -1	2.2 2.6 4.8 -2.13	-1.9 -1.3 -2.6 1.19	$\begin{array}{c} 2\cdot 2,  5\cdot 6,  3\cdot 4\\ 1\cdot 0,  2\cdot 2,  1\cdot 6\\ 14\cdot 0,  31\cdot 3,  13\cdot 7\\ -3,  -1\cdot 6,  -2\cdot 8\end{array}$	$\begin{array}{c} 1\cdot 3 \\ -1\cdot 02 \\ 1\cdot 3 \\ 1\cdot 3 \\ \# N/A \end{array}$	$\begin{array}{c} 1 \cdot 8 \\ 1 \cdot 0 \\ -1 \cdot 01 \end{array}$	$\begin{array}{c} 1\cdot 26 - 1\cdot 46 \\ -1\cdot 08 \text{ to } 1\cdot 05 \\ \mu N/A \\ -1\cdot 2 \text{ to } 1\cdot 0 \end{array}$	#N/A #N/A #N/A #N/A
Current stue	Current study comparison of fold change of schistosomiasis only [S],	only [S]		miasis and v	schistosomiasis and viral hepatitis B [SH] and [C] controls. C57 is a previously published murine study of $S$	d [C] contro	ls. C57 is a	previously published	d murine study of <i>S</i> .

*jabomicum* infection time course (Burke et al. 2010b), four additional datasets were selected including Alcohol, alcoholic hepatitis, Con A, concanavalin À-induced fulminant hepatitis model, HBV, hepatitis B virus associated acute liver failure and HCV, hepatitis C virus infection effect on Huh7 hepatoma cells

(reviewed in (Laplante and Sabatini, 2012)). Furthermore, apoptosis in hepatocarcinoma cells has been linked to telomerase activity and the downregulation of mTOR signalling (Bu *et al.* 2007), which may mirror the situation reported here. Another possible mechanism that could be responsible for the downregulation of the mTOR pathway could involve the dis-regulation of growth hormone in the liver, as has been suggested for the Ames dwarf mouse model (Sharp and Bartke, 2005). Here, [S] patients had reduced levels of growth hormone receptor (GHR -2.7-fold), which would reflect reduced growth hormone action in this system and may impact on the mTOR pathway as a whole.

Interferon-induced transmembrane (IFITM1) is an interferon-induced protein which has known antiviral activity as demonstrated in HCV-infected hepatocytes (Raychoudhuri et al. 2011). Despite its nominated antiviral activity this gene was surprisingly downregulated (-1.7-fold) in [SH] but upregulated (1.4-fold) in [S] patients (Table 2). Similarly, another antiviral gene MX1 (or MxA: myxovirus resistance 1), which is also interferon-inducible, was similarly modulated ([S] 1.2-fold, [SH] -1.9-fold). A direct effect of interferon on these genes can be discounted as there was a similar expression pattern of other interferon genes or related genes in both pathology groups (Table 2). The potential effect of antiviral genes in response to a schistosome infection is intriguing area for future research.

The most significantly upregulated gene in [S] patients was insulin-like growth factor binding protein 2 (IGFBP2) which was increased 6.9-fold relative to controls. IGFBP2 is involved in many important biological functions such as synthesis of proteins and lipids, increasing the mass and size of the liver, migration of vascular smooth muscle cells and proliferation of fibroblasts (Firth and Baxter, 2002). It should be noted that all of the [S] and [SH] patients presented with enlarged livers (Table 1), and this may reflect the elevated levels of IGFBP2. Increased IGFBP2 has also been reported to be associated with hepatitis C-associated osteosclerosis (HCAO), a rare disorder characterized by a marked increase in bone mass during adult life, a feature not normally seen in either control Hepatitis C or Hepatitis B patients (Khosla et al. 1998). However, hepatic engorgement is more likely due to portal hypertension which is a key feature of chronic schistosomiasis (Li et al. 2011). It is noteworthy that two other IGF-binding proteins - IGFBP3 and IGFBP5 ([S] -1.6, -4.0, [SH] - 2.6, -4.8) – were downregulated in both [S]and [SH] samples. While IGFBP2 was also upregulated in [SH] (3.8-fold), the gene most highly upregulated (6.1-fold increase relative to controls) in these samples was tumour-associated calcium signal

transducer 1 (TACSTD1, also known as EpCAM), whose expressed protein is known to be associated with cellular adhesion (Balzar *et al.* 1999). TACSTD1 is a hepatic stem cell marker previously studied in carcinomas (Yamashita *et al.* 2007), that is increased in Hepatitis B and hepatic carcinoma (Kimura *et al.* 2014) as well as in alcoholic hepatitis (see GEO accession: GDS4389 and (Affo *et al.* 2013)).

The most downregulated gene in [S] was the uncharacterized C10orf116 (-6.0-fold) followed by GPAM (glycerol-3-phosphate acyltransferase, mitochondrial) at -5.2-fold. C10orf116, also known as Adipose most abundant gene transcript 2 (APM2), is known to be expressed in adipose tissue and over expression of the encoded protein leads to increased cellular proliferation and increased glucose transport but its full functional significance, particularly in the liver, is unknown (Chen et al. 2013). GPAM, associated with many aspects of fatty acid metabolism and the synthesis of glycerolipids (Wendel et al. 2009), was also downregulated in [SH] (-7.20-fold). The gene with the lowest expression in [SH] was TXNIP (-7.9-fold) which was also highly downregulated in [S] (-5.1-fold). TXNIP is related to lipid metabolism and is reported to be necessary for the replication of Hepatitis C (Blackham et al. 2010).

Relative to controls, most cytokines and chemokines were downregulated in [S] and [SH] patients. We have previously reported that neutrophils are an important cell type recruited to the site of granuloma formation in a murine model of schistosomiasis japonica (Burke et al. 2010b; Perry et al. 2011; Chuah et al. 2013, 2014b). One chemokine that was upregulated in the livers of [S] and [SH] patients was CXCL6, which recruits neutrophils, a prominent feature of the murine S. japonicum model. CXCL6 is also upregulated in alcoholic cirrhosis of the liver and HBV (see Table 5). A decrease in the serum levels of other chemokines, such as granulocyte associated CXCL5, has been reported in patients with chronic liver disease (Tacke et al. 2011) but our observations represent a decrease in the liver tissue itself rather than in the peripheral blood.

A comparison of our findings with a previous study examining concanavalin A-induced liver damage in an acute murine model (Cao et al. 2010) identified many genes in common. These included upregulated genes such as IGFBP2 and downregulated genes such as B2M. Genes such as Granulin (GRN) were downregulated in [S] (-1.9) and [SH]  $(-3\cdot3)$ , but these remained unchanged in mice with concanavalin A-induced hepatitis. An early study showed that beta-2-microglobulin (B2M) () was as a serum marker for many types of liver diseases including acute viral hepatitis, chronic persistent or active hepatitis and liver cirrhosis (Revillard, 1980), but this was not apparent in the [S] and [SH] patients (downregulated [S] -2.7 and [SH] -4.8) or the results of other hepato-pathologies we

correlated in this study, all which assessed gene expression directly in liver tissue. This might be expected since tissue gene profiling studies indicate that gene expression in liver tissue is relatively low, with higher expression levels being apparent in many peripheral blood immune cells (Wu et al. 2013). GRN had decreased expression in both [S] and [SH], but its levels were generally unchanged in other hepatic disease conditions we considered (See online Supplementary Table 4), and in our published murine schistosomiasis studies (Burke et al. 2010b). GRN is a well charactered growth factor associated with many types of cancer including hepatocellular carcinomas (Cheung et al. 2004). The expression of a GRN-like molecule by the human liver fluke, Opisthorchis viverrini, has been linked to the development of cholangiocarcinoma (Smout et al. 2009) and tissue repair (Bateman and Bennett, 2009). However, there is limited information as to whether reduced expression of the mammalian gene may lead to liver pathology; of the studies reporting a reduction in GRN levels, all have been associated with neurological conditions, rather than hepatic-related pathologies (Capell et al. 2011; Dopper et al. 2011). Consequently, the reduction in GRN expression we recorded is a unique finding and worthy of future investigation to determine the role of this protein in the livers of advanced schistosomiasis patients.

Matrix metallopeptidase 7 (MMP7) was upregulated in [S] with even higher expression in [SH] patients (Table 5), a situation not replicated in chronic murine schistosomiasis (Chuah et al. 2013). MMP7 degrades proteoglycans, fibronectin, elastin and casein and has been implicated in wound healing and tissue remodelling (Huang et al. 2005) and in the fibroproliferative process in the liver during chronic hepatitis C (Lichtinghagen et al. 2001). Our results suggest that MMP7 could be a potential candidate biomarker for chronic human schistosomiasis, although the induction of this gene in cirrhosis is also seen in other aetiologies (see Table 5) which would limit its diagnostic specificity. The suggestion that MMPs, and more specifically MMP7, may prove useful as biomarkers of fibrosis has been made previously for pulmonary disease (Rosas et al. 2008; Song et al. 2013), and the results presented here support their potential value as biological markers of hepatic fibrosis in schistosomiasis. In support of these findings MMPs, measured in SEA stimulated peripheral blood mononuclear cells (PBMCs) as well as serum, have been related to S. japonicum infection of humans (Fabre et al. 2011; McDonald et al. 2014).

Further comparison of the transcriptional findings in subjects with schistosomiasis and other disease states resulted in the identification of individual genes associated with key biological hepatic functions. Three chemokine receptors or ligands that

were differentially expressed in [S] or [SH] patients are associated generally with liver disease, including chemokine (C-C motif) receptor 6 (CCR6), CXCL6 and chemokine (C-X-C motif) ligand 12 (CXCL12). CXCL6 was the only gene upregulated over 2-fold in [SH] (2·3-fold, 1·5-fold in [S]), while the others were downregulated (see Table 5). These genes were also shown to be differentially expressed in the C57 murine model of schistosomiasis and in other liver diseases we examined. Upregulation of CXCL6 is a feature of Alcohol disease and HBV, whereas it is downregulated in concanavalin Ainduced hepatitis. The functional roles of these chemokines in liver disease have been reviewed (Sahin et al. 2010), with CCR6 shown to be associated with T cells, B cells and dendritic cells; CXCL6 is associated with neutrophils and monocytes; and CXCL12 is expressed in most resident hepatic cells including hepatocytes, vascular endothelial cells and stellate cells, as well as in immunological cells including monocytes, basophils and B cells. The upregulation of neutrophil chemokines is a well-known feature of chronic schistosomiasis japonica, but not chronic schistosomiasis mansoni, in mice (Chuah et al. 2013, 2014a). In this human study of chronic schistosomiasis, the changes in neutrophil gene expression we observed may be reflective of tissue remodelling rather a role in inflammation.

#### Conclusions

Our previous studies with the murine model of schistosomiasis japonica increased understanding of the transcriptional and cellular events that regulate S. japonicum-induced granuloma formation and fibrosis (Burke et al. 2010a, b; Perry et al. 2011; Chuah et al. 2013). Here we provide some insight on the molecular events that occur in Chinese patients with chronic hepatic schistosomiasis japonica. The results provide a comprehensive transcriptional profile of human schistosomiasis and demonstrate similarities and differences with other liver diseases. The unique features we report of gene expression in human liver, in conjunction with previous reports of the formation and recovery and the cellular composition of schistosome-induced granulomas, improve our understanding of the molecular immunopathology and general physiological status underlying the aetiology of schistosomiasis.

#### SUPPLEMENTARY MATERIAL

To view supplementary material for this article, please visit http://dx.doi.org/10.1017/S0031182015000682.

#### ACKNOWLEDGEMENTS

Y. S. L is an ARC Future Fellow; D. P. M is a NHMRC Senior Principal Research Fellow and Senior Scientist at QIMR Berghofer.

#### FINANCIAL SUPPORT

This work was supported by the National Health and Medical Research Council (NHMRC) of Australia.

#### REFERENCES

Affo, S., Dominguez, M., Lozano, J. J., Sancho-Bru, P., Rodrigo-Torres, D., Morales-Ibanez, O., Moreno, M., Millan, C., Loaezadel-Castillo, A., Altamirano, J., Garcia-Pagan, J. C., Arroyo, V., Gines, P., Caballeria, J., Schwabe, R. F. and Bataller, R. (2013). Transcriptome analysis identifies TNF superfamily receptors ap potential therapeutic targets in alcoholic hepatitis. *Gut* **62**, 452–460.

Balzar, M., Winter, M. J., de Boer, C. J. and Litvinov, S. V. (1999). The biology of the 17–1A antigen (Ep-CAM). *Journal of Molecular Medicine* (*Berlin*) 77, 699–712.

Banner, B. F., Savas, L., Zivny, J., Tortorelli, K. and Bonkovsky, H. L. (2000). Ubiquitin as a marker of cell injury in nonalcoholic steatohepatitis. *American Journal of Clinical Pathology* **114**, 860–866.

Bateman, A. and Bennett, H. P. (2009). The granulin gene family: from cancer to dementia. *BioEssays* **31**, 1245–1254.

Blackham, S., Baillie, A., Al-Hababi, F., Remlinger, K., You, S., Hamatake, R. and McGarvey, M. J. (2010). Gene expression profiling indicates the roles of host oxidative stress, apoptosis, lipid metabolism, and intracellular transport genes in the replication of hepatitis C virus. *Journal of Virology* 84, 5404–5414.

Bose, S. K., Shrivastava, S., Meyer, K., Ray, R. B. and Ray, R. (2012). Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. *Journal of Virology* **86**, 6315– 6322.

Bu, X., Jia, F., Wang, W., Guo, X., Wu, M. and Wei, L. (2007). Coupled down-regulation of mTOR and telomerase activity during fluorouracilinduced apoptosis of hepatocarcinoma cells. *BMC Cancer* 7, 208.

Burke, M. L., Jones, M. K., Gobert, G. N., Li, Y. S., Ellis, M. K. and McManus, D. P. (2009). Immunopathogenesis of human schistosomiasis. *Parasite Immunology* **31**, 163–176.

Burke, M. L., McManus, D. P., Ramm, G. A., Duke, M., Li, Y., Jones, M. K. and Gobert, G. N. (2010*a*). Co-ordinated gene expression in the liver and spleen during *Schistosoma japonicum* infection regulates cell migration. *PLoS Neglected Tropical Diseases* **4**, e686.

Burke, M. L., McManus, D. P., Ramm, G. A., Duke, M., Li, Y., Jones, M. K. and Gobert, G. N. (2010b). Temporal expression of chemokines dictates the hepatic inflammatory infiltrate in a murine model of schistosomiasis. *PLoS Neglected Tropical Diseases* **4**, e598.

Cao, Q. Y., Chen, F., Li, J., Wu, S. S., Wang, J. and Chen, Z. (2010). A microarray analysis of early activated pathways in concanavalin A-induced hepatitis. *Journal of Zhejiang University. Science. B* **11**, 366–377.

Capell, A., Liebscher, S., Fellerer, K., Brouwers, N., Willem, M., Lammich, S., Gijselinck, I., Bittner, T., Carlson, A. M., Sasse, F., Kunze, B., Steinmetz, H., Jansen, R., Dormann, D., Sleegers, K., Cruts, M., Herms, J., Van Broeckhoven, C. and Haass, C. (2011). Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. *Journal of Neuroscience* **31**, 1885–1894.

Chen, F., Zhu, H. H., Zhou, L. F., Li, J., Zhao, L. Y., Wu, S. S., Wang, J., Liu, W. and Chen, Z. (2010). Genes related to the very early stage of ConA-induced fulminant hepatitis: a gene-chip-based study in a mouse model. *BMC Genomics* **11**, 240.

Chen, G., Chen, H., Wang, C., Peng, Y., Sun, L., Liu, H. and Liu, F. (2012). Rapamycin ameliorates kidney fibrosis by inhibiting the activation of mTOR signaling in interstitial macrophages and myofibroblasts. *PLoS ONE* **7**, e33626.

Chen, L., Zhou, X. G., Zhou, X. Y., Zhu, C., Ji, C. B., Shi, C. M., Qiu, J. and Guo, X. R. (2013). Overexpression of C10orf116 promotes proliferation, inhibits apoptosis and enhances glucose transport in 3T3-L1 adipocytes. *Molecular Medicine Reports* 7, 1477–1481.

Cheung, S. T., Wong, S. Y., Leung, K. L., Chen, X., So, S., Ng, I. O. and Fan, S. T. (2004). Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma. *Clinical Cancer Research* **10**, 7629–7636.

Chuah, C., Jones, M. K., Burke, M. L., Owen, H. C., Anthony, B. J., McManus, D. P., Ramm, G. A. and Gobert, G. N. (2013). Spatial and temporal transcriptomics of *Schistosoma japonicum*-induced hepatic granuloma formation reveals novel roles for neutrophils. *Journal of Leukocyte Biology* **94**, 353–365.

Chuah, C., Jones, M.K., Burke, M.L., McManus, D.P. and Gobert, G.N. (2014*a*). Cellular and chemokine-mediated regulation in schistosome-induced hepatic pathology. *Trends in Parasitology* **30**, 141–150.

Chuah, C., Jones, M. K., Burke, M. L., McManus, D. P., Owen, H. C. and Gobert, G. N. (2014b). Defining a pro-inflammatory neutrophil phenotype in response to schistosome eggs. *Cellular Microbiology* **16**, 1666–1677.

Dopper, E.G., Seelaar, H., Chiu, W.Z., de Koning, I., van Minkelen, R., Baker, M.C., Rozemuller, A.J., Rademakers, R. and van Swieten, J.C. (2011). Symmetrical corticobasal syndrome caused by a novel C.314dup progranulin mutation. *Journal of Molecular Neuroscience* **45**, 354–358.

Fabre, V., Wu, H., PondTor, S., Coutinho, H., Acosta, L., Jiz, M., Olveda, R., Cheng, L., White, E.S., Jarilla, B., McGarvey, S. T., Friedman, J. F. and Kurtis, J. D. (2011). Tissue inhibitor of matrixmetalloprotease-1 predicts risk of hepatic fibrosis in human *Schistosoma japonicum* infection. *Journal of Infectious Diseases* 203, 707–714.

Firth, S. M. and Baxter, R. C. (2002). Cellular actions of the insulin-like growth factor binding proteins. *Endocrine Reviews* 23, 824–854.

Gryseels, B., Polman, K., Clerinx, J. and Kestens, L. (2006). Human schistosomiasis. *Lancet* 368, 1106–1118.

Heikens, M.J., Cao, T.M., Morita, C., Dehart, S.L. and Tsai, S. (2007). Penumbra encodes a novel tetraspanin that is highly expressed in erythroid progenitors and promotes effective erythropoiesis. *Blood* **109**, 3244–3252.

Huang, C. C., Chuang, J. H., Chou, M. H., Wu, C. L., Chen, C. M., Wang, C. C., Chen, Y. S., Chen, C. L. and Tai, M. H. (2005). Matrilysin (MMP-7) is a major matrix metalloproteinase upregulated in biliary atresia-associated liver fibrosis. *Modern Pathology* **18**, 941–950. Jiang, L., Xu, L., Mao, J., Li, J., Fang, L., Zhou, Y., Liu, W., He, W., Zhao, A. Z., Yang, J. and Dai, C. (2013). Rheb/mTORC1 signaling promotes kidney fibroblast activation and fibrosis. *Journal of the American Society of Nephrology* **24**, 1114–1126.

Jimenez-Marin, A., Collado-Romero, M., Ramirez-Boo, M., Arce, C. and Garrido, J.J. (2009). Biological pathway analysis by arrayunlock and ingenuity pathway analysis. *BMC Proceedings* 3(Suppl. 4), S6.

Katz, N., Chaves, A. and Pellegrino, J. (1972). A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. *Revista do Instituto de Medicina Tropical de Sao Paulo* **14**, 397–400.

Khosla, S., Hassoun, A.A., Baker, B.K., Liu, F., Zein, N.N., Whyte, M.P., Reasner, C.A., Nippoldt, T.B., Tiegs, R.D., Hintz, R.L. and Conover, C.A. (1998). Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. *Journal of Clinical Investigation* 101, 2165–2173.

Kimura, O., Kondo, Y., Kogure, T., Kakazu, E., Ninomiya, M., Iwata, T., Morosawa, T. and Shimosegawa, T. (2014). Expression of EpCAM increases in the Hepatitis B related and the treatment-resistant hepatocellular carcinoma. *BioMed Research International* **2014**, 172913.

Krastev, Z. (1998). Liver damage score--a new index for evaluation of the severity of chronic liver diseases. *Hepato-Gastroenterology* 45, 160–169.
 Laplante, M. and Sabatini, D. M. (2012). mTOR signaling in growth control and disease. *Cell* 149, 274–293.

Li, Y., Chen, D., Ross, A. G., Burke, M. L., Yu, X., Li, R. S., Zhou, J. and McManus, D. P. (2011). Severe hepatosplenic schistosomiasis: clinicopathologic study of 102 cases undergoing splenectomy. *Human Pathology* **42**, 111–119.

Lichtinghagen, R., Michels, D., Haberkorn, C. I., Arndt, B., Bahr, M., Flemming, P., Manns, M. P. and Boeker, K. H. (2001). Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. *Journal of Hepatology* 34, 239–247.

McDonald, E. A., Cheng, L., Jarilla, B., Sagliba, M. J., Gonzal, A., Amoylen, A. J., Olveda, R., Acosta, L., Baylink, D., White, E. S., Friedman, J. F. and Kurtis, J. D. (2014). Maternal infection with Schistosoma japonicum induces a profibrotic response in neonates. Infection and Immunity 82, 350-355.

Murray, C. J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., Abraham, J., Ackerman, I., Aggarwal, R., Ahn, S. Y., Ali, M. K., Alvarado, M., Anderson, H. R., Anderson, L. M., Andrews, K. G., Atkinson, C., Baddour, L. M., Bahalim, A. N., Barker-Collo, S., Barrero, L. H., Bartels, D. H., Basanez, M. G., Baxter, A., Bell, M. L., Benjamin, E. J., *et al.* (2013). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis. *Lancet* **380**, 2197–2223.

Nissim, O., Melis, M., Diaz, G., Kleiner, D. E., Tice, A., Fantola, G., Zamboni, F., Mishra, L. and Farci, P. (2012). Liver regeneration signature in hepatitis B virus (HBV)-associated acute liver failure identified by gene expression profiling. *PLoS ONE* **7**, e49611.

Perry, C. R., Burke, M. L., Stenzel, D. J., McManus, D. P., Ramm, G. A. and Gobert, G. N. (2011). Differential expression of chemokine and matrix re-modelling genes is associated with contrasting schistosome-induced hepatopathology in murine models. *PLoS Neglected Tropical Diseases* 5, e1178.

Raychoudhuri, A., Shrivastava, S., Steele, R., Kim, H., Ray, R. and Ray, R. B. (2011). ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. *Journal of Virology* **85**, 12881–12889.

Revillard, J. P. (1980). Significance of beta 2-microglobulin in liver diseases. *Vox Sanguinis* **38**, 339–342.

Rosas, I. O., Richards, T. J., Konishi, K., Zhang, Y., Gibson, K., Lokshin, A. E., Lindell, K. O., Cisneros, J., Macdonald, S. D., Pardo, A., Sciurba, F., Dauber, J., Selman, M., Gochuico, B. R. and Kaminski, N. (2008). MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. *PLoS Medicine* 5, e93.

Ross, A.G., Bartley, P.B., Sleigh, A.C., Olds, G.R., Li, Y., Williams, G.M. and McManus, D.P. (2002). Schistosomiasis. New England fournal of Medicine 346, 1212–1220.

Sahin, H., Trautwein, C. and Wasmuth, H. E. (2010). Functional role of chemokines in liver disease models. *Nature Reviews. Gastroenterology and Hepatology* 7, 682–690.

Sharp, Z. D. and Bartke, A. (2005). Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. *Journals of Gerontology. Series A, Biological Sciences and Medical Sciences* **60**, 293–300.

Smout, M. J., Laha, T., Mulvenna, J., Sripa, B., Suttiprapa, S., Jones, A., Brindley, P. J. and Loukas, A. (2009). A granulin-like growth factor secreted by the carcinogenic liver fluke, *Opisthorchis viverrini*, promotes proliferation of host cells. *PLoS Pathogens* 5, e1000611.

Song, J. W., Do, K. H., Jang, S. J., Colby, T. V., Han, S. and Kim, D. S. (2013). Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. *Chest* **143**, 1422–1429.

Tacke, F., Zimmermann, H. W., Trautwein, C. and Schnabl, B. (2011). CXCL5 plasma levels decrease in patients with chronic liver disease. *Journal of Gastroenterology and Hepatology* 26, 523–529.

Wang, Z., Jin, W., Jin, H. and Wang, X. (2014). mTOR in viral hepatitis and hepatocellular carcinoma: function and treatment. *Biomed Res Int* 2014, 735672.

Wendel, A. A., Lewin, T. M. and Coleman, R. A. (2009). Glycerol-3-phosphate acyltransferases: rate limiting enzymes of triacylglycerol biosynthesis. *Biochimica et Biophysica Acta* **1791**, 501–506.

Whaley-Connell, A., Habibi, J., Panfili, Z., Hayden, M.R., Bagree, S., Nistala, R., Hyder, S., Krueger, B., Demarco, V., Pulakat, L., Ferrario, C.M., Parrish, A. and Sowers, J.R. (2011). Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. *American Journal of Nephrology* 34, 115–125. Wilson, M.S., Mentink-Kane, M. M., Pesce, J. T., Ramalingam, T. R., Thompson, R. and Wynn, T.A. (2007). Immunopathology of schis-

tosomiasis. *Immunology and Cell Biology* **85**, 148–154. **Wu, C., Macleod, I. and Su, A. I.** (2013). BioGPS and MyGene.info: organizing online, gene-centric information. *Nucleic Acids Research* **41** (Database issue), D561–D565.

Yamashita, T., Budhu, A., Forgues, M. and Wang, X. W. (2007). Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. *Cancer Research* **67**, 10831–10839.

Yen, C. J., Lin, Y. J., Yen, C. S., Tsai, H. W., Tsai, T. F., Chang, K. Y., Huang, W. C., Lin, P. W., Chiang, C. W. and Chang, T. T. (2012). Hepatitis B virus X protein upregulates mTOR signaling through IKKbeta to increase cell proliferation and VEGF production in hepatocellular carcinoma. *PLoS ONE* **7**, e41931.